-
Dasiglucagon (glucagon analog stable in liquid formulation) for use in other indications
Dasiglucagon is a Zealand-invented glucagon analog with a unique stability profile in a ready-to-use aqueous solution. It is also in development for two additional indications: treatment of type 1 diabetes with a next-generation artificial pancreas, and treatment for children born with a genetic mutation that causes congenital hyperinsulinism (CHI).
About type 1 diabetes and hypoglycemia
People with type 1 diabetes suffer from insulin deficiency and inappropriate glucagon secretion. Both hormones are essential to ensure stable and healthy blood glucose levels. Consequently, patients must monitor and adjust their blood glucose levels to remain in proper glycemic control, as both high and low blood glucose may affect their health, both in the short and long term.
Severe hypoglycemia is an acute, life-threatening condition resulting from a critical drop in blood glucose levels associated primarily with insulin therapy. Severe hypoglycemia occurs most frequently in people with type 1 diabetes due to injecting insulin multiple times daily. It is the biggest concern for insulin-dependent patients and the most feared complication of diabetes treatment. The condition is characterized by confusion, seizures, and often loss of consciousness that can result in death if left untreated.
When a patient has a hypoglycemic event, a second person must assist in treatment. Currently marketed formulations of glucagon for the treatment of severe hypoglycemia require mixing first by the person assisting to treat and then immediate administration due to poor drug stability. Dasiglucagon is being developed to offer a stable ready-to-use rescue treatment for severe hypoglycemia.
-
Laatste alinea is wellicht het antwoord op vraag 1
-
Zealand Pharma Flying Under Everyone's Radar
seekingalpha.com/article/4320845-zeal...
-
Wat is er aan de hand met Zealand blijft maar door stijgen... hou ze stevig vast me aandelen..
Heb gelezen dat de verhandelbaarheid niet heel groot is in de fonds per dag...
-
Ja het gaat als een trein! Soms is het best om de rit lekker uit te zitten, hoewel ik soms wel wat hoogtevrees krijg.. Maar ben niet van plan te verkopen.
Ik denk dat ze ook wel een overname kandidaat zijn namelijk.
Goed om te onthouden dat de marketcap ondanks de grote stijging nog meevalt. <1.5 miljard
-
-
Weet iemand wanneer er weer resultaten van zealand pharma bekend worden ?
De koers blijft vrij stabiel.
Direct naar Forum
Indices
 |
AEX |
651,73 |
-0,75% |
 |
EUR/USD |
1,2081 |
-0,59% |
 |
Germany30^ |
13.771,50 |
-1,55% |
 |
Gold spot |
1.828,41 |
0,00% |
 |
LDN100-24h |
6.700,03 |
0,00% |
 |
NY-Nasdaq Composite |
12.998,50 |
-0,87% |
Stijgers
Dalers